Halogenated mevalonate compositions and uses thereof in ras-dependent cell growth
US5668171A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 8, 1993 |
| Grant date | Sep 16, 1997 |
| Priority date | — |
| Expiry date | Nov 8, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/19
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions that include as an active ingredient an effective concentration of a halogenated mevalonate preparation, particularly, Fmev (fluoromevalonate) are provided. The pharmacological activity of halogenated mevalonate for inhibiting ras-dependent cell growth, particularly ras-dependent tumor cell growth, is described. Methods for using preparations including a therapeutically effective concentration of Fmev for the inhibition of ras-dependent cell growth, as well as in the treatment and inhibition of ras-dependent tumors is also disclosed. The claimed compositions may be provided in liquid, salve, tablet, or capsule form, as well as other forms suitable for administration to an animal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.